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Insulin-Like Growth Factor-Binding Protein 3 Induces Caspase-Dependent
Apoptosis through a Death Receptor-Mediated Pathway in MCF-7
Human Breast Cancer Cells
Ho-Seong Kim, Angela R. Ingermann, Junko Tsubaki, Stephen M. Twigg, Gillian E. Walker, and Youngman Oh
Department of Pediatrics, Oregon Health and Science University, Portland, Oregon
ABSTRACT
Insulin-like growth factor-binding protein (IGFBP)-3 has been
shown to potently inhibit cell proliferation in various cell systems.
However, the specific mechanisms involved in the antiproliferative
action of IGFBP-3 have yet to be elucidated. In the present study, we
demonstrate that IGFBP-3 induces apoptosis in an insulin-like growth
factor (IGF)-independent manner through the activation of caspases
involved in a death receptor-mediated pathway in MCF-7 human
breast cancer cells. Induction of IGFBP-3 using an ecdysone-inducible
expression system inhibited DNA synthesis in an IGF-IGF receptor
axis-independent fashion and resulted in the subsequent induction of
apoptosis and an increase in caspase activity. Similar results were
obtained when cells were transfected with GGG-IGFBP-3, an IGFBP-3
mutant unable to bind IGFs, corroborating the IGF-independent ac-
tion of IGFBP-3. Additional caspase activity studies and immunoblot
analyses using specific caspase substrates and/or caspase inhibitors
revealed that the growth-inhibitory effect of IGFBP-3 results mainly
from its induction of apoptosis (in particular, activation of caspase-8
and -7). Analyses of caspase-9 activity and release of cytochrome c into
the cytosol confirmed that the mitochondria-mediated pathway is not
involved. Taken together, these results show that IGFBP-3 expression
leads to the induction of apoptosis through the activation of caspases
involved in a death receptor-mediated pathway and that IGFBP-3
functions as a negative regulator of breast cancer cell growth, inde-
pendent of the IGF-IGF receptor axis.
INTRODUCTION
The insulin-like growth factor-binding proteins (IGFBPs) are com-
ponents of the insulin-like growth factor (IGF) axis, and their super-
family comprises six high-affinity species (IGFBPs 1–6) and several
low-affinity binders [IGFBP-related proteins (1–5)]. The classical role
of the IGFBPs involves IGF binding and modulation of IGF signaling;
however, recent data suggest that some IGFBPs may play a more
active, IGF-independent role in growth regulation of various cell
systems (6–19). In particular, IGFBP-3 has been shown to potently
inhibit the proliferation of various cell types in an IGF-independent
manner. The concept of IGF-independent actions for IGFBP-3 has
been supported by the demonstration that (a) exogenous IGFBP-3
binds to specific proteins on the cell surface, and this interaction is
strongly correlated with the ability of IGFBP-3 to inhibit cell growth
(8, 9); (b) overexpression of human IGFBP-3 cDNA inhibits cell
proliferation (10–12); (c) IGFBP-3 mediates transforming growth
factor  (13)-, retinoic acid (14)-, antiestrogen (15)-, vitamin D analog
(16)-, and tumor necrosis factor (TNF)- (17)-induced growth inhi-
bition; (d) regulation of IGFBP-3 gene expression plays a role in
signaling by p53, a potent tumor suppressor protein (18); and (e)
IGFBP-3 fragments inhibit the stimulation of DNA synthesis induced
by either IGF-I or insulin (19). Recently, several reports have dem-
onstrated that IGFBP-3 induces apoptosis in PC-3 prostate cancer (20)
and MCF-7 breast cancer cells (21) and enhances ceramide-induced
apoptosis in Hs578T breast cancer cells (22). These apoptosis-induc-
ing effects of IGFBP-3 may be due to sequestering of IGFs, thus
blocking their antiapoptotic activities (21). Alternatively, IGFBP-3
may act via IGF-independent pathways because IGFBP-3 can induce
apoptosis in an IGF receptor-negative mouse fibroblast cell line (20)
and can accentuate apoptosis under conditions where IGF-I does not
elicit a survival effect (22). More direct evidence comes from the
demonstration that IGFBP-3 mutants that do not bind IGFs stimulate
apoptosis in human prostate cancer cells (23). Additional studies by
Butt et al. (24) have demonstrated that IGFBP-3 can modulate the
expression of the Bax:Bcl-2 protein ratio in apoptotic human breast
cancer cells in a p53-independent manner. In addition, caspase-3
activity, as well as IGFBP-3 levels, is increased in Hs578T breast
cancer cells undergoing apoptosis in response to the chemotherapeutic
agent paclitaxel (25). Despite clear evidence of IGFBP-3’s activation
of apoptosis in an IGF-independent fashion, the mechanisms by which
these effects are achieved have yet to be elucidated.
Programmed cell death plays a crucial role in normal develop-
ment, defense of homeostasis, and pathological situations (26 –28).
Apoptotic signals are generally believed to be mediated through a
caspase system controlled by two autonomous and interacting
pathways that are associated with either cell surface death recep-
tors or mitochondria. Apoptotic stimuli such as DNA-damaging
agents trigger the release of mitochondrial cytochrome c into the
cytosol, which controls the assembly of an apoptosome composed
of Apaf-1 (apoptotic protease-activating factor 1), Bcl-XL, and
procaspase-9 (29). Binding of cytochrome c and dATP to Apaf-1
results in the activation of caspase-9 and the subsequent activation
of downstream caspases such as caspase-3, which kill cells by
cleaving key intracellular proteins, whereas Bcl-XL presumably
inhibits this function. In contrast, binding of death ligands to their
death receptors leads to the recruitment of a variety of death
domain-bearing adapter proteins, which in turn recruit the most
upstream caspases, such as caspase-8 and -10, an event that results
in the activation of these caspases and downstream effector
caspases. In addition, these activated upstream caspases may act on
the mitochondria to facilitate cytochrome c release, thereby further
amplifying the apoptotic signal. Here we show that IGFBP-3
inhibits cell growth in an IGF-independent manner and that its
growth-inhibitory effect results from the caspase-dependent induc-
tion of apoptosis in MCF-7 human breast cancer cells. We also
show that IGFBP-3 facilitates the induction of biochemical events
such as the activation of the initiator caspase-8 and the processing
of caspase-7 but minimal release of cytochrome c from mitochon-
dria and processing of caspase-9, suggesting that IGFBP-3-induced
apoptosis may be accomplished through the activation of caspases
involved in a death receptor-mediated pathway in MCF-7 human
breast cancer cells.
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MATERIALS AND METHODS
Reagents and Kits. Tissue culture reagents and plastics were purchased
from Mediatech (Hemdon, VA), Becton Dickinson (Franklin Lakes, NJ),
and Nunc (Naperville, IL). Special reagents and kits were obtained from the
following sources: Zeocin, Geneticin sulfate, and ponasterone A (Invitro-
gen, Carlsbad, CA); IGFBP-3 radioimmunoassay kit (Diagnostic Systems
Laboratories, Webster, TX); CellTiter 96 cell proliferation assay (Promega,
Madison, WI); TNF- (Calbiochem, San Diego, CA); IGFBP-5 (Austral
Biologicals, San Ramon, CA); annexin V apoptosis kit (Clontech, Palo
Alto, CA); cell death detection ELISA kit (Roche Molecular Biochemicals,
Indianapolis, IN); aminomethylcoumarin (AMC) derivatives (caspase sub-
strates) and cell-permeable aldehyde derivatives (caspase inhibitors) of
tetrapeptide sequences that are recognized by distinct caspases [Ac-DEVD-
AMC (caspase-3/-7), Ac-LEHD-AMC (caspase-9), Ac-IETD-AMC
(caspase-8), and Z-VAD-fluoromethylketone (FMK) (broad-spectrum
caspase inhibitor), BIOMOL Research Laboratories (Plymouth Meeting,
PA); Z-IETD-FMK (caspase-8 inhibitor) and Z-DEVD-FMK (caspase-3/-7
inhibitor), BD PharMingen (San Diego, CA; Refs. 30 –33)]. Antibodies
against poly(ADP-ribose) polymerase (PARP), cleaved PARP, caspase-9,
cleaved caspase-9, caspase-7, and caspase-10 were purchased from Cell
Signaling Technology (Beverly, MA); antibody against caspase-8 was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA); and antibod-
ies against cytochrome c, Bid, and caspase-2 were purchased from BD
PharMingen. IGF-I, 125I-labeled IGF-I and -II, and a monoclonal antibody
against IGFBP-3 were generously provided by Diagnostic Systems Labo-
ratories. The ecdysone-inducible expression system was purchased from
Invitrogen.
Cell Cultures. The MCF-7 human breast cancer cell line and its deriv-
atives expressing an IGFBP-3 in an inducible manner were maintained in
DMEM supplemented with 4.5 g/liter glucose, 110 mg/liter sodium pyru-
vate, and 10% fetal bovine serum (FBS). At 60 –70% confluence, the cells
were washed with fresh serum-free media (SFM) and then incubated in
phenol red-free SFM in the presence or absence of 15 M ponasterone A for
an additional 72 h, unless specifically indicated in the text.
Establishment of MCF-7-Derived Cell Line Expressing IGFBP-3 in an
Inducible Manner. The MCF-7 human breast cancer cell was purchased
from the American Type Culture Collection (Manassas, VA). A cDNA
containing 1.5-kb human IGFBP-3 (equivalent to the 674-2191 cDNA
sequence) was ligated into the pIND expression vector, which contains five
modified ecdysone response elements. This construct was cotransfected
with a second plasmid, pVgRXR, expressing the ecdysone receptor
(VgEcR) and the retinoid X receptor (RXR), into MCF-7 cells using
FuGENE 6 transfection reagent (Roche, Indianapolis, IN). After 48 h, the
cells were split into selective medium containing G418 (800 g/ml) for
pIND/IGFBP-3 and Zeocin (100 g/ml) for pVgRXR, and foci were picked
to generate a stable cell line expressing pVgRXR and pIND/IGFBP-3.
Three days after the addition of ponasterone A, which is an ecdysone
analog inducing the heterodimer of RXR and VgEcR to bind to the hybrid
ecdysone response element in the pIND vector, conditioned media (CM)
were collected to test for ponasterone A-inducible expression of IGFBP-3.
pVgRXR-transfected MCF-7 cells were used as a negative control (EcR
cells).
Plasmids and Transfections. The GGG-IGFBP-3 mutant cDNA was
generated by site-directed mutagenesis at residues Ile 56, Leu 80, and Leu 81
to Gly 56, Gly 80, and Gly 81, as described previously (34). Binding studies
(including BIAcore analysis) showed that the GGG-IGFBP-3 mutant pro-
tein, generated in Escherichia coli and baculovirus expression systems,
abolished affinity for IGFs (34). For transfection, GGG-IGFBP-3 mutant
cDNAs were subcloned into the pCMV6 vector as described previously
(34). MCF-7 cells were seeded in DMEM supplemented with 10% FBS and
transfected with the pCMV6 vector or pCMV6/GGG-IGFBP-3 using Fu-
GENE 6 transfection reagent. Twenty-four h after transfection, the media
were replaced with SFM and maintained as indicated above.
[3H]Thymidine Incorporation Assay. Cells were grown in 24-well
plates until 60 –70% confluent, when the media were replaced with phenol
red-free SFM in the presence or absence of 15 M ponasterone A. After
68 h, 0.1 Ci of [3H]thymidine (25 Ci/mM; New England Nuclear, Boston,
MA) in a volume of 25 l was added to each well for a 4-h pulse. The rate
of DNA synthesis was estimated by measuring the trichloroacetic acid-
precipitable radioactivity, as described previously (35).
Cell Proliferation Assay. Cells were grown in 96-well plates until
60 –70% confluent, when the media were replaced with phenol red-free
SFM in the presence or absence of 15 M ponasterone A for 72 h. Assays
were performed by adding 100 l of CellTiter 96 Aqueous one solution
(1:5 dilution with phenol red-free SFM) directly to culture wells after
aspirating media and incubating for 1 h at 37°C. The quantity of viable cells
was measured in a 96-well plate reader at 490 nm.
Flow Cytometry and Apoptosis Assay. Cells were grown in 6-well
plates until 60 –70% confluent, when the media were replaced with DMEM
containing 10% FBS in the presence or absence of 15 M ponasterone A for
72 h. Both attached and floating cells were harvested by trypsinization,
pelleted at 1000 rpm for 5 min, and washed three times with PBS. Each
sample of cells was resuspended in a propidium iodide staining solution (50
g/ml propidium iodide, 100 units/ml RNase A, 0.1% Triton X-100, and
0.1% sodium azide in PBS) and shaken for 30 min in the dark before
measurement on a FACSCalibur flow cytometer (Becton Dickinson) using
an argon laser at 488 nm for excitation. Apoptotic cells were detected using
a FITC-labeled annexin V binding assay according to the manufacturer’s
directions. All data were analyzed using the Cell Quest software package
(Becton Dickinson).
Cell Death Detection ELISA Assay. The photometric cell death detec-
tion ELISA is based on quantitative sandwich enzyme immunoassay prin-
ciple using mouse monoclonal antibodies directed against DNA and his-
tones, respectively. In brief, equal numbers of cells (1  104 cells/ml) were
plated on 24-well culture plates in 10% FBS-supplemented DMEM. At
60 –70% confluence, cells were treated with 15 M ponasterone A in the
absence or presence of 25 M Z-VAD-FMK or 20 M Z-IETD-FMK in
phenol red-free SFM for 72 h. TNF- (20 ng/ml) and 10% FBS were used
as positive and negative controls, respectively. Adherent and floating cells
were used to prepare the cytosolic fractions according to the vendor’s
instructions. Equal volumes of the cytosolic fractions were transferred to
the streptavidin-coated microtiter plates and incubated with anti-histone-
biotin and peroxidase-conjugated anti-DNA immunoreagents. The reaction
products were read using a Bio-Rad microplate reader. Each experiment
was carried out with duplicate samples and repeated at least three times.
Measurement of Caspase Activity. Caspase activity was measured in
lysates by analyzing the in vitro hydrolysis of Ac-DEVD-AMC (caspase-3
and -7), Ac-IETD-AMC (caspase-8), Ac-LEHD-AMC (caspase-9), or a
mixture of Ac-DEVD-AMC and Ac-LEHD-AMC (total caspases; Refs.
30 –33). In brief, cells were seeded on 12-well plates, cultured until
60 –70% confluent, and then incubated in phenol red-free SFM with or
without ponasterone A or other reagents for the times indicated. Cells from
each well were lysed in 100 l of ice-cold lysis buffer [50 mM HEPES (pH
7.4), 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic
acid, 0.1% Triton X-100, 1 mM DTT, and 0.1 mM EDTA]. Fluorogenic
peptide substrates were added to each well of a fluorometer plate to a final
concentration of 40 M in the assay buffer [50 mM HEPES (pH 7.4), 100
mM NaCl, 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesul-
fonic acid, 10 mM DTT, 1 mM EDTA, and 10% glycerol]. The fluorescence
of the AMC released from the substrate was measured in a kinetic mode for
up to 16 h using a Bio-Rad Fluoromark Reader with the excitation and
emission wavelength set at 390 and 460 nm, respectively. Data were
analyzed using Microplate Manager III Macintosh Data Analysis software
(Bio-Rad, Melville, NY). Enzyme activity was quantitated against a stand-
ard fluorescence curve generated using AMC over a concentration range of
0 –1000 nM.
Preparation of Cell Lysates for Western Blots. Cell lysates were pre-
pared as described previously, with minor modification (36). In brief,
confluent cells were washed with cold PBS and then scraped from plates in
the presence of cold lysis buffer containing 20 mM Tris (pH 8.0), 1% NP40,
0.1% SDS, 150 mM NaCl, 0.5% sodium deoxycholate, and Complete
Protease Inhibitor mixture (Boehringer Mannheim). Floating cells in the
CM were collected by centrifugation and resuspended in cold lysis buffer.
Cell lysates were rocked for 15 min at 4°C in a microcentrifuge tube and
centrifuged to remove cell debris. The aliquots were stored at 70°C until
further use.
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Preparation of Cytosolic and Mitochondrial Extracts. For the detection
of cytochrome c, cytosolic and mitochondrial extracts were prepared as
described previously (37). In brief, cells (2  106) were harvested by
scraping directly in the medium, washed in cold PBS, and permeabilized
for 1 min at room temperature in isotonic sucrose buffer [250 mM sucrose,
10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, and 1 mM EDTA
(pH 7.1)] containing 0.025% digitonin and Complete Protease Inhibitor
mixture. Digitonin was used to selectively permeabilize the plasma mem-
branes of cells to obtain the cytosolic fractions. Cells were centrifuged at
4°C (15,000  g for 10 min), and the supernatant was designated the
cytosolic fraction. The pellet of permeabilized cells was incubated for 10
min on ice in lysis buffer containing 0.5% Triton X-100 and Complete
Protease Inhibitor mixture to release membrane- and organelle-bound sol-
uble proteins including mitochondrial cytochrome c. The Triton X-100-
soluble (mitochondrial) fraction was separated by centrifugation at
15,000  g for 10 min, and all fractions were stored at 70°C for Western
blot analysis.
Western Blot Analysis. The CM from IGFBP-3-induced cells were
size-fractionated by 12–15% SDS-PAGE under nonreducing conditions,
whereas cell lysates were size-fractionated under reducing conditions.
Size-fractionated proteins were electrotransferred to Hybond-ECL nitro-
cellulose (Amersham Pharmacia, Arlington, VA). For Western immuno-
blotting, the membranes were blocked in 5% nonfat dry milk in Tris-
buffered saline with 0.1% Tween 20 (TBST) and incubated with primary
antibodies diluted in TBST for 2 h at room temperature or overnight at 4°C.
Membranes were washed in TBST and then incubated with horseradish
peroxidase-conjugated secondary antibodies (Southern Biotechnology As-
sociates, Birmingham, AL), diluted 1:7000, for 1 h at room temperature.
Immunoreactive proteins were detected using the Renaissance Western Blot Chemiluminescence reagents (New England Nuclear). For Western
ligand blotting, the membranes were incubated overnight with 1.0  106
cpm of 125I-labeled IGF-I and IGF-II after blocking with normal saline
containing 1% BSA at room temperature for 2 h. The filters were washed
twice with normal saline containing 0.1% Tween 20 and three times with
normal saline for 15 min each, dried, and exposed to film.
Densitometric and Statistical Analysis. Densitometric measurement of
immunoblots was performed using a Bio-Rad GS-670 imaging densitom-
eter (Bio-Rad). All experiments were conducted at least three times. The
data were analyzed with Student’s t test, using the Microsoft Excel 98
software package.
RESULTS
Ecdysone-Inducible Expression of IGFBP-3 in the Stably
Transfected MCF-7 Cells. Because recent studies suggest that
posttranslational modification of IGFBP-3, such as glycosylation,
phosphorylation, and proteolysis, influences the biological activity
of IGFBP-3 (38 – 40), an ecdysone-inducible expression system
was used to investigate the biological function of intracellularly
expressed IGFBP-3 (41). It was first determined whether ponas-
terone A could induce IGFBP-3 expression in stably transfected
MCF-7 cells. Among the clones picked as stable transfectants,
IGFBP-3 was expressed in subclones 2, 3, and 6 in an inducible
manner and was constitutively expressed in subclones 1 and 16
(Fig. 1A). Expression of IGFBP-3 could be detected by 12 h at
concentrations of ponasterone A ranging from 2 to 10 M without
affecting cell viability. Subclone 3 was used for further investiga-
tion because physiologically relevant levels of IGFBP-3 were
induced by a low concentration of ponasterone A, and noninduced
levels were undetectable. The addition of ponasterone A increased
the expression of IGFBP-3, but not that of the other IGFBPs, in
CM (Fig. 1B). Quantitative analysis of IGFBP-3 concentrations in
CM by an IGFBP-3 radioimmunoassay kit indicated that the max-
imal expression of IGFBP-3 (124 ng/ml) occurs on day 3 at a
concentration of 15 M ponasterone A.
Inhibition of DNA Synthesis by IGFBP-3. Subclone 3 MCF-7
cells were first tested for effects on cell growth by analyzing the
effects of IGFBP-3 induction on DNA synthesis. The induced
Fig. 1. Insulin-like growth factor-binding protein (IGFBP)-3 expression in stably
transfected MCF-7 cells (MCF-7:IGFBP-3 cells) after treatment with ponasterone A. A,
Western immunoblot analysis of IGFBP-3 in a panel of 16 stably transfected clones.
MCF-7 cells were transfected with an expression vector containing IGFBP-3 cDNA
(pIND plasmid) and a second plasmid expressing ecdysone receptor (VgEcR) and retinoid
X receptor (RXR). Stably transfected cells were selected by G418 and Zeocin. Ponaster-
one A induces the heterodimer of RXR and VgEcR to bind the hybrid ecdysone response
element in the pIND vector, resulting in the activation of IGFBP-3 transcription. Sub-
clones 1 and 16 constitutively express IGFBP-3; subclones 2, 3, and 6 express IGFBP-3
in an inducible manner. B, Western ligand blotting showing that only the expression of
IGFBP-3, but not that of other IGFBPs, was induced in conditioned media after treatment
with ponasterone A.
Fig. 2. Inhibitory effect of insulin-like growth factor-binding protein 3 on DNA
synthesis in inducible stably transfected MCF-7 cells. Cells of MCF-7:IGFBP-3 or the
parental cell line expressing only the ecdysone receptor heterodimer (EcR) were treated
with ponasterone A at concentrations of 0, 5, 10, and 15 M for 72 h in phenol red-free
serum-free media. After 68 h, [3H]thymidine was added, and its incorporation into DNA
was determined after an additional 4 h. Each bar represents the mean  SE of three
independent experiments. , P  0.005, ponasterone A-treated cells versus cells in
serum-free media on day 3.
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expression of IGFBP-3 by ponasterone A resulted in an inhibition
of DNA synthesis of up to 32.5–38% at concentrations of 5–15 M
ponasterone A (Fig. 2). Importantly, in the same experiments, the
parental cells expressing the ecdysone receptor heterodimer (EcR
cells) did not show any significant change in [3H]thymidine incor-
poration after treatment with ponasterone A (Fig. 2).
IGFBP-3 Induces Apoptosis in MCF-7 Cells. To identify the
mechanism of the inhibitory effect of IGFBP-3 on monolayer
growth, we first determined whether the cellular expression of
IGFBP-3 can induce apoptosis using an annexin V binding assay
and a cell death detection ELISA (42). Induced expression of
IGFBP-3 caused an increase in the percentage of cells undergoing
apoptosis from 1.5% in the absence of ponasterone A to 21.8% in
the presence of ponasterone A (P  0.05 compared with cells
without ponasterone A), suggesting that IGFBP-3 can induce apo-
ptosis in this cell system (Fig. 3A). In the same experiments, the
parental MCF-7:EcR cells did not show any significant change in
the percentage of cells undergoing apoptosis after treatment with
ponasterone A (Fig. 3A). This finding was corroborated by an
independent cell death detection ELISA, in which cells cultured in
DMEM supplemented with 10% FBS showed a near absence of
apoptotic cells, whereas SFM-treated cells showed a basal level
apoptotic index (Fig. 3B). In contrast, the addition of ponasterone
A to the cells in SFM induced a further increase in the apoptotic
index above the basal level (P  0.05 compared with cells in SFM;
Fig. 3B). The induction of apoptosis by IGFBP-3 measured using
the cell death detection ELISA was greater than that induced by
TNF-, which has been demonstrated to be a potent apoptosis-
inducing agent in MCF-7 cells (43). The induction of apoptosis
was observed from day 2, with maximal induction on day 3 (about
a 6-fold induction) after the addition of ponasterone A (Fig. 3C).
We next investigated whether the mode of IGFBP-3-induced
apoptosis involved the activation of caspase activity specific for
apoptosis. Similar to the observations obtained using the cell death
detection ELISA, the induced expression of IGFBP-3 increased the
level of total caspase activity (P  0.05 compared with cells in
SFM) to the levels seen after treatment with 20 ng/ml TNF- (Fig.
3D). The increase of caspase activity was observed from day 1,
with a maximal increase on day 3 (Fig. 3E). A slight increase of
caspase activity was also observed over the incubation time in cells
in SFM, which might be due to serum deprivation (Fig. 3E).
Effects of IGFBP-3 Are Mediated through IGF-Independent
Action. We next determined whether the effects of IGFBP-3 on
cell growth, induction of apoptosis, and caspase activation were
IGF independent. The observed biological effects of IGFBP-3 did
not result from blocking the endogenous IGF action because
IGFBP-5, which binds both IGF-I and IGF-II with high affinity,
had no significant effect on basal DNA synthesis in MCF-7:
IGFBP-3 cells without ponasterone A when added at 150 ng/ml but
blocked the stimulatory effect of 5 ng/ml IGF-I (Fig. 4A). Further-
more, when MCF-7 cells were transfected with GGG-IGFBP-3, an
IGFBP-3 mutant unable to bind IGFs, DNA synthesis was de-
creased compared with the level shown in cells transfected with
empty vector (Fig. 4B). In addition, apoptotic index and total
caspase activity were increased in GGG-IGFBP-3-transfected cells
(Fig. 4, C and D), which are comparable with those seen in cells
overexpressing intact IGFBP-3 (Figs. 2 and 3). Taken together,
Fig. 3. Induction of apoptosis and activation of
caspases by insulin-like growth factor-binding pro-
tein (IGFBP)-3 in stably transfected MCF-7 cells.
A, MCF-7:IGFBP-3 cells or the parental cell line
expressing only the ecdysone receptor heterodimer
(EcR) were seeded with or without 15 M ponas-
terone A in DMEM containing 10% fetal bovine
serum for 72 h. Cells were incubated with annexin
V, and the binding of annexin V was determined by
flow cytometry. IGFBP-3-induced cells show an
increase in binding of annexin V, an indicator of
cells undergoing apoptosis. , P  0.05
(mean  SE; n  3). B, MCF-7:IGFBP-3 cells
were seeded with or without ponasterone A in
phenol red-free serum-free media (SFM) for 72 h.
The degree of apoptosis was determined by cell
death detection ELISA as described in “Materials
and Methods.” , P  0.05, ponasterone A-treated
cells versus cells in SFM (mean  SE; n  6). C,
cell death detection ELISA at the indicated time.
, P  0.0005, ponasterone A-treated cells versus
cells in SFM on day 3 (mean SE; n 6). D, total
caspase activity (in pmol/min/mg) was examined in
MCF-7:IGFBP-3 cells with or without ponasterone
A cultured in phenol red-free SFM for 72 h. ,
P  0.05, treated cells versus cells in SFM
(mean SE; n 6). E, total caspase activity at the
indicated time. , P  0.05, ponasterone A-treated
cells versus cells in SFM on day 3 (mean  SE;
n  6).
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these data confirm that effects on cell growth and induction of
apoptosis are IGFBP-3 specific and IGF-IGF receptor independent.
Caspases Involved in a Death Receptor-Mediated Pathway Are
Activated in IGFBP-3-Induced Apoptosis. To determine which
caspases are activated by IGFBP-3, we measured the kinetics of
IGFBP-3-induced changes in enzyme activities using substrates
that display specificity for each caspase in vitro: Ac-IETD-AMC
(caspase-8), Ac-LEHD-AMC (caspase-9), Ac-DEVD-AMC
(caspase-3/-7), or a mixture of Ac-DEVD-AMC and Ac-LEHD-
AMC (total caspase), respectively. It was observed that the induced
expression of IGFBP-3 significantly increased total caspase,
IETDase, and DEVDase activity (Fig. 5A, , P  0.05 compared
with cells with SFM) but not LEHDase activity. Because MCF-7
cells do not express a functional caspase-3 due to a deletion within
exon 3 of the CASP3 gene (44), the DEVDase activity may come
from the activity of caspase-7 or -2 in our cell system. In contrast,
increased IETDase activity may come from the activation of
caspase-8, -10, or -6 on the basis of Ac-IETD-AMC specificity
(32). To identify the caspases involved in IGFBP-3-induced apo-
ptosis, the activation of procaspase-8, -10, -6, -9, -7, and -2 was
examined in cells treated with ponasterone A by Western immu-
noblotting (Fig. 5B). As expected from the caspase activity studies,
we found a significant decrease in the level of procaspase-8, and
-7, but not procaspase-10, -6, -9, and -2, after the addition of
ponasterone A. Maximal decrease of procaspase-8 and -7, accom-
panied by an increase of cleaved PARP, was observed on day 3
after the addition of ponasterone A, suggesting that IGFBP-3
activates caspase-8 and -7, although the cleaved caspases were not
detected in our cell system.
IGFBP-3-Induced Apoptosis Is Mediated by Caspase-Depend-
ent Pathways. Previous studies have demonstrated that exposure
of MCF-7cells to TNF- (25–50 ng/ml) leads to apoptotic cell
death (30 – 60%) within 24 h (43). In the present study, cells treated
with 20 ng/ml TNF- or 15 M ponasterone A both showed a
marked decrease in proliferation (Fig. 6A) and an increased apop-
totic index (Fig. 6B), as well as elevated caspase activity (Fig. 6C)
on day 2 after treatment. Furthermore, TNF- and IGFBP-3-
induced cell death was accompanied by an increase in the level of
cleaved PARP (Fig. 6D). These changes induced by TNF- or
IGFBP-3 were completely prevented by cotreatment with the
broad-spectrum caspase inhibitor Z-VAD-FMK (Fig. 6, AD),
suggesting that both TNF-- and IGFBP-3-induced apoptosis are
mediated by caspase-dependent pathways. At the same time, the
caspase-8 inhibitor Z-IETD-FMK also completely abolished the
changes in cell proliferation, apoptotic index, caspase activity, and
cleaved PARP expression by TNF- or IGFBP-3 (Fig. 6, AD),
confirming that caspase-8 is a key initiator caspase involved in the
induction of apoptosis by IGFBP-3.
IGFBP-3 Does Not Affect the Release of Cytochrome c into the
Cytosol in MCF-7 Cells. Mitochondrial release of cytochrome c
into the cytosol during apoptosis is thought to be caspase inde-
pendent, even though in some cases of death receptor-mediated
apoptosis, caspase-8 or -10 may act on mitochondria to facilitate
cytochrome c release, thereby further amplifying the apoptotic
signal (45). To determine whether IGFBP-3 triggers cytochrome c
release, we examined the amount of cytochrome c in the cytosolic
and mitochondrial fractions of cells after treatment with ponaster-
one A. Because TNF- has been reported to elicit mitochondrial
cytochrome c release and Bid cleavage in MCF-7 cells (43), cells
were treated with 20 ng/ml TNF- for 48 h as a positive control.
There was minimal cytochrome c in the cytosolic fraction in
SFM-cultured and ponasterone A-treated cells, whereas detectable
cytochrome c was increased in TNF--treated cells (Fig. 7, top
panel). Simultaneously, the amount of cytochrome c in the mito-
chondrial fraction was decreased in TNF--treated cells, but not in
the SFM-cultured and ponasterone A-treated cells (Fig. 7, top
panel). Bid is normally cleaved by a caspase-8-dependent process,
and cleaved Bid elicits mitochondrial cytochrome c release. The
amount of intact Bid in the cytosolic fraction was decreased in
TNF--treated cells, whereas no change was observed in ponas-
terone A-treated cells or SFM-cultured cells (Fig. 7, middle panel).
These results suggest that IGFBP-3 does not affect the release of
cytochrome c from mitochondria.
DISCUSSION
IGFBP-3, which is the most abundant IGFBP in human serum,
acts not only as a carrier of IGFs, thereby prolonging their half-
Fig. 4. Effects of insulin-like growth factor-
binding protein (IGFBP)-3 in an insulin-like
growth factor (IGF)-independent manner. A, MCF-
7:IGFBP-3 cells without ponasterone A were
treated with human IGFBP-5 (150 ng/ml), IGF-I (5
ng/ml), or both in phenol red-free serum-free media
(SFM) for 24 h before [3H]thymidine incorporation
assay. , P  0.05, control versus IGF-I-treated
cells. B, MCF-7 cells were seeded on 24-well cul-
ture plates in DMEM supplemented with 10% fetal
bovine serum. At 60–70% confluence, cells were
transfected with pCMV6 vector or pCMV6/GGG-
IGFBP-3. Twenty-four h after transfection, the me-
dia were replaced with phenol red-free SFM. After
68 h, [3H]thymidine was added, and its incorpora-
tion into DNA was determined after an additional
4 h. , P 0.005; , P 0.0005 (control versus
GGG-IGFBP-3-transfected cells). C, the degree of
apoptosis was determined by cell death detection
ELISA in cells incubated with phenol red-free SFM
for 72 h after transfection. , P  0.005; ,
P  0.0005 (control versus GGG-IGFBP-3-trans-
fected cells). D, total caspase activity was exam-
ined in cells incubated with phenol red-free SFM
for 72 h after transfection. , P  0.05; ,
P  0.005 (control versus GGG-IGFBP-3-trans-
fected cells). Each bar represents the mean SE of
three independent experiments.
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lives, but also functions as a modulator of the IGF activity by
regulating the availability of free IGFs for their interaction with
IGF receptors (1–2). Recently, there has been a growing accumu-
lation of data demonstrating that IGFBP-3 may have its own
biological actions, inhibiting cell proliferation in an IGF-independ-
ent manner (6 –19). Conceptually, IGFBP-3 can exert its actions on
target cells in several ways: (a) inducing apoptosis; (b) regulating
the cell cycle; and (c) possible cross-talk with major signal trans-
duction pathways. Mechanisms for inducing apoptosis, in part,
have been demonstrated by studies showing that IGFBP-3 in-
creases the ratio of proapoptotic (Bax and Bad) to antiapoptotic
(Bcl-2 and Bcl-XL) proteins in apoptotic breast cancer cells (24),
and caspase-3 activity and IGFBP-3 levels in CM are increased in
paclitaxel-treated Hs578T breast cancer cells (25). As a regulator
of the cell cycle, IGFBP-3 has been shown to regulate the induc-
tion of the cyclin-dependent kinase inhibitory protein p21/WAF/
CIP1 by vitamin D analogs in prostate cancer cells (46). In addi-
tion, an active Ras-mitogen-activated protein kinase pathway has
been shown to block IGFBP-3-induced cell growth inhibition,
whereas inhibition of the mitogen-activated protein kinase path-
ways restored the biological function of IGFBP-3 (47). Although
these early investigations have revealed, in part, suggestive mech-
anisms for IGFBP-3 action, mechanisms of action for IGFBP-3
remain largely undetermined.
In the present investigation, we have begun to address specific
questions regarding the intracellular mechanisms involved in
IGFBP-3-induced apoptosis in MCF-7 breast cancer cells. To
determine these mechanisms, we used MCF-7 cells expressing
cellular IGFBP-3 in an inducible manner. Because MCF-7 cells do
not express detectable IGF-I (48 –50), and experiments in this
study were performed in phenol red-free SFM, our results suggest
that the apoptosis-inducing effect of IGFBP-3 in MCF-7 cells is
independent of the IGF-IGF receptor axis, although the model
system does not rule out the effects of residual IGFs. Nevertheless,
use of a IGFBP-3 mutant and other IGFBPs confirms that IGFBP-
3-induced cell growth inhibition is specific for IGFBP-3 and
IGF-independent: (a) MCF-7:IGFBP-3 cells used in this study are
not inhibited by IGFBP-5, which binds both IGF-I and -II with
high affinity; and (b) more definitively, MCF-7 cells transfected
with the IGFBP-3 mutant, which is unable to bind IGFs, show
inhibition of DNA synthesis, induction of apoptosis, and activation
of caspase.
Here we demonstrate for the first time that IGFBP-3 induces
apoptosis in MCF-7 cells by activating multiple caspases involved
in a death receptor-mediated pathway, such as caspase-8 and
-7, but not via the mitochondria-mediated pathway. Further-
more, these findings do not reflect clonal variation of the
MCF-7:IGFBP-3 cells used in this study because the expression of
IGFBP-3 by adenoviral transduction results in the same biological
effects in MCF-7 cells (data not shown). Despite the lack of
functional caspase-3 due to a deletion in the CASP3 gene (44),
MCF-7 cells underwent apoptosis, suggesting that other execu-
tioner caspases, such as caspase-7 or -2, may be involved. We
demonstrate that IGFBP-3 activates caspase-7 but not caspase-2, as
shown by Western immunoblotting, explaining the elevated
caspase-3-like (DEVD-ase) activity, which is consistent with pre-
vious studies showing that caspase-7 was processed in doxorubi-
cin-induced apoptosis of MCF-7 cells (51), but caspase-2 was not
processed after TNF- or staurosporine treatment (52). Caspase-8
can activate caspase-3 and -7 directly and/or through triggering the
activation of caspase-9 by the release of cytochrome c from mito-
chondria (26 –29). To assess the relative importance of caspase-8
in the cytotoxic signaling of IGFBP-3, we examined the effect of
Z-IETD-FMK (caspase-8 inhibitor) during IGFBP-3-induced apo-
ptosis. The caspase-8 inhibitor significantly blocked the actions of
IGFBP-3 to increase total caspase activity, to induce apoptosis as
measured by the cell death detection ELISA assays, to cleave
PARP, and to suppress cell proliferation. Thus, on the basis of this
caspase activity assessment and the studies using the caspase-8
inhibitor, IGFBP-3-induced apoptosis in MCF-7 cells involves the
caspase-8-mediated activation of executioner caspases such as
Fig. 5. Activation of caspases involved in death receptor-mediated pathway in insulin-
like growth factor-binding protein 3-induced apoptosis in MCF-7 cells. A, lysates of cells
incubated with or without ponasterone A or in 10% fetal bovine serum or 20 ng/ml tumor
necrosis factor  for 72 h were assayed for total caspase (DEVDase and LEHDase),
DEVDase (caspase-3-like), IETDase (caspase-8), and LEHDase (caspase-9) activities
(mean  SE; n  6). , P  0.05, treated cells versus cells in serum-free media. B,
Western immunoblot analysis of caspase-8, -10, -6, -9, -7, and -2 and cleaved PARP in
MCF-7:IGFBP-3 cells with or without ponasterone A at the indicated time. Proteins
showing a significant change after addition of ponasterone A are indicated by an asterisk.
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caspase-7, but not the activation of caspase-9. At the same time,
the broad-spectrum caspase inhibitor Z-VAD-FMK also abolished
the negative effects on cell proliferation, induction of apoptosis,
caspase activity, and levels of cleaved PARP by IGFBP-3, sug-
gesting that the antiproliferative effect of IGFBP-3 results mainly
from the induction of apoptosis. During the preparation of this
paper, Butt et al. (53) also reported that IGFBP-3-mediated apo-
ptosis in T47D human breast cancer cells was significantly blocked
by treatment with Z-VAD-FMK, further supporting our findings.
Cytochrome c release from mitochondria during apoptosis can
be achieved through two different mechanisms. Direct stimuli such
as genotoxic agents or UV light can release cytochrome c in a
caspase-independent manner, whereas activated caspase-8 or -10
may also facilitate cytochrome c release from mitochondria,
Fig. 6. Activation of caspases by insulin-like
growth factor-binding protein 3 in a caspase-de-
pendent manner. MCF-7:IGFBP-3 cells were incu-
bated with 15 M ponasterone A or 20 ng/ml tumor
necrosis factor  in phenol red-free serum-free
media  25 M Z-VAD-fluoromethylketone or 20
M Z-IETD-fluoromethylketone for 72 h. A, cell
proliferation assay by CellTiter 96 assay. B, apop-
totic index by cell death detection ELISA. C, total
caspase activity. , P  0.05; , P  0.005; ,
P 0.0005 (treated cells versus cells in serum-free
media; mean  SE; n  6). D, Western immuno-
blot analysis of cleaved PARP.
Fig. 7. Subcellular distribution of cytochrome c after induction of insulin-like growth
factor-binding protein 3 in MCF-7 cells. MCF-7:IGFBP-3 cells were incubated with 15
M ponasterone A or 20 ng/ml tumor necrosis factor  in phenol red-free serum-free
media for 48 h. Cytosolic and mitochondrial fractions prepared as described in “Materials
and Methods” were immunoblotted with monoclonal antibody to cytochrome c and Bid.
The results are representative of at least three independent experiments.
Fig. 8. Schematic representation of insulin-like growth factor-binding protein (IG-
FBP)-3-induced apoptosis. IGFBP-3 may inhibit cell growth by induction of apoptosis
either indirectly, by sequestrating insulin-like growth factors away from the insulin-like
growth factor receptor, or directly via putative IGFBP-3 receptor and/or translocation to
the nucleus. IGFBP-3 increases the ratio of proapoptotic (Bax and Bad) to antiapoptotic
(Bcl-2 and Bcl-XL) members of the Bcl-2 family (24). Our study demonstrates the
existence of an apoptotic cascade, which utilizes caspases involved in the death receptor-
mediated pathway such as caspase-8 and -7.
2235
IGFBP-3 INDUCES APOPTOSIS VIA ACTIVATION OF CASPASES
Research. 
on July 9, 2014. © 2004 American Association for Cancercancerres.aacrjournals.org Downloaded from 
thereby further amplifying the apoptotic signal (48). In our study,
the induced expression of IGFBP-3 did not affect the redistribution
of cytochrome c, suggesting that IGFBP-3-induced apoptosis does
not result from the disruption of mitochondrial function and
caspase-9 activation, which is consistent with previous studies on
cisplatin- or somatostatin-induced apoptosis in MCF-7 cells (54,
55). Minimal detection of cytochrome c in the cytosol of both
control cells and ponasterone A-treated cells may result from
serum deprivation as observed previously (56).
In summary, these findings help define the temporal sequence of
events that links the initiator and effector caspases in IGFBP-3-
induced apoptosis in MCF-7 cells. Fig. 8 depicts the proposed
mechanism for IGFBP-3-induced apoptosis in MCF-7 cells, based
on the results from the present study and other previous studies
(24). The present study supports the existence of an IGFBP-3-
regulated apoptotic cascade, which utilizes caspases involved in
death receptor-mediated pathways, such as caspase-8 and
caspase-7, suggesting that IGFBP-3 functions as a negative regu-
lator of breast cancer cell growth, independent of the IGF axis.
These events occur on the cell surface as demonstrated previously
in the prostate cancer cell system (20). It is tempting to speculate
that IGFBP-3-induced apoptosis may be initiated by interaction of
IGFBP-3 with the cognate receptor(s), which has yet to be identi-
fied, thereby subsequently activating initiator caspase-8 and down-
stream effector caspases.
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